Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

 
• By Mandy Jackson
  
Microscopic image of a gastrointestinal stromal tumor (GIST). Malignant potential depends on size, location and mitotic activity. Targeted therapy with Imatinib (Gleevec) may prevent recurrence. - Image
Deciphera's ripretinib targets GIST cells with KIT and PDGFRa mutations. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D